Baxter, Mark A. http://orcid.org/0000-0002-5773-8650
Middleton, Fearghas
Cagney, Hannah P.
Petty, Russell D. http://orcid.org/0000-0003-2055-4572
Article History
Received: 9 November 2020
Revised: 17 March 2021
Accepted: 22 April 2021
First Online: 6 July 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Not applicable.
: M.A.B. has received funding from Servier and BMS to attend meetings. R.D.P. has undertaken speaking, consulting and advisory roles for Eli Lilly, BMS, Pfizer, Sanofi, Servier; and received research funding (not related to the work in this manuscript) from Astra Zeneca, Roche, MSD, Merck serrano, Eli Lilly, Five Prime Therapeutics, Clovis, Boston Biomedical, and Janssen. F.M. and H.P.C. have no conflicts of interest to declare.
: No funding was received for the writing of this article. M.A.B. is a Clinical Academic Fellow funded by the Scottish Chief Scientist Office.